DOSING REGIMEN FOR COMBINATION THERAPY TARGETING DLL3 AND PD-1

The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent and an anti-PD-1 antibody. Step dosing of the anti-DLL3 agent is also disclosed.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Roychoudhury, Siddhartha, Minocha, Mukul, Wong, Hansen, Sadraei, Nooshin Hashemi, Smit, Marie-Anne Damiette, Shetty, Aditya
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!